The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Open accessAbstract
BACKGROUND.: Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease. METHODS.: A Cox regression model was used to estimate the effect of fractures (time‐dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3–4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors). RESULTS.: A total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death. CONCLUSIONS.: These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Self-citationSkeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Self-citationSaad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Self-citationHillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Self-citationEstimating Hip Fracture Morbidity, Mortality and Costs
Braithwaite, R. S., Col, N. F., & Wong, J. B. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51110.x · Cited by 911
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citationRosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.105 · Cited by 729
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Self-citationBerenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationHortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Self-citationTheriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Self-citationKohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Self-citationPreclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Self-citationBisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
Incident vertebral fractures and mortality in older women: a prospective study
Kado, D. M., Duong, T., Nevitt, M. C., Greendale, G. A., Cummings, S. R., Stone, K. L., & Ensrud, K. E. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1412-5 · Cited by 289
Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients
Jalava, T., Sarna, S., Pylkkänen, L., Mawer, B., Kanis, J. A., Selby, P., Davies, M., Adams, J., Francis, R. M., Robinson, J., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1254 · Cited by 275
Bisphosphonates for breast cancer
Pavlakis, N., Schmidt, R. L., & Stockler, M. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub2 · Cited by 244
Bisphosphonates in breast cancer
Coleman, R. E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi162 · Cited by 158
Self-citationHillner, B. E., Ingle, J. N., Chlebowski, R. T., & Theriault, R. L. (2004) · Breast Diseases A Year Book Quarterly · Cited by 118
Tanvetyanon, T., & Hines, E. (2005) · Cancer · doi:10.1002/cncr.20996 · Cited by 89
Fred Saad, C., Olsson, C. A., & Schulman, C. C. (2004) · European Urology · doi:10.1016/j.eururo.2004.08.016 · Cited by 71
Hirsh, V., Tchekmedyian, N. S., Rosen, L. S., Zheng, M., & Hei, Y.-J. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.030 · Cited by 63
Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence
García, M. R., Díaz, M. N., & Andía, J. B. C. (2005) · Journal of Nephrology · doi:10.1093/joneph/18.4.458 · Cited by 61
How many people develop fractures with what outcome?
O’Neill, T. W., & Roy, D. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.06.003 · Cited by 55
McCloskey, E. V., Guest, J. F., & Kanis, J. A. (2001) · Drugs · doi:10.2165/00003495-200161090-00003 · Cited by 41
Strategies for Management of Prostate Cancer-Related Bone Pain
Pelger, R. C. M., Soerdjbalie‐Maikoe, V., & Hamdy, N. A. T. (2001) · Drugs & Aging · doi:10.2165/00002512-200118120-00002 · Cited by 26
Saba, N. F., & Khuri, F. R. (2005) · Oncology · doi:10.1159/000084518 · Cited by 17
Clodronate in the prevention and treatment of skeletal metastasis
Gulley, J. L., & Dahut, W. L. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.2.221 · Cited by 5
Cited by
Onukwugha, E., Yong, C., Hussain, A., Seal, B., & Mullins, C. D. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-1 · Cited by 589
Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schechtman, K., Tillman, J. B., Bastian, L., Ashraf, T., & Vrionis, F. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70008-0 · Cited by 524
Nørgaard, M., Jensen, A. Ø., Jacobsen, J. B., Cetin, K., Fryzek, J. P., & Sørensen, H. T. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.03.034 · Cited by 406
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
Metadata
- Authors
- Saad, F., Lipton, A., Cook, R., Chen, Y., Smith, M., & Coleman, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-09-19
- Volume
- 110
- Issue
- 8
- Pages
- 1860-1867
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2011926580
- Cited by
- 667
- References
- 33
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.